No Data
No Data
Dongbao Biotech (300239.SZ) announced its 2023 annual results, with net profit of 120 million yuan, an increase of 9.55%
Dongbao Biotech (300239.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 9...
Dongbao Biotech (300239.SZ): Net profit of 259.615 million yuan in the first quarter decreased 16.62% year-on-year
Gelonghui, April 23 | Dongbao Biotech (300239.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 242 million yuan, down 7.48% year on year; net profit attributable to shareholders of listed companies was 25.9615 million yuan, down 16.62% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 236.22,300 yuan, down 21.61% year on year; basic earnings per share were 0.0437 yuan.
The A-share artificial meat concept fluctuated and declined, Dongbao Biotech fell more than 6%
Gelonghui March 1 | Dongbao Biotech and Shuangta Foods fell more than 6%, followed by Zuming Co., Ltd., Suobao Protein, Tangrenshen, and Jiahua Co., Ltd.
Dongbao Biotech (300239.SZ): The subsidiary Yiqing Biotech has once again been certified as a high-tech enterprise
Gelonghui, Feb. 20, | Dongbao Biotech (300239.SZ) announced that the company's holding subsidiary, Qingdao Yiqing Biotechnology Co., Ltd. (“Yiqing Biotech”), recently received the “High-tech Enterprise Certificate” jointly approved and issued by the Qingdao Municipal Bureau of Science and Technology, the Qingdao Municipal Finance Bureau, and the Qingdao Municipal Taxation Bureau of the State Administration of Taxation. Yiqing Biotech has once again passed the high-tech enterprise certification.
Dongbao Biotech (300239.SZ) once again passed the high-tech enterprise certification
Gelonghui, January 23丨Dongbao Biotech (300239.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly approved and issued by the Inner Mongolia Autonomous Region Science and Technology Department, the Inner Mongolia Autonomous Region Finance Department, and the Inner Mongolia Autonomous Region Taxation Bureau of the State Administration of Taxation. The company once again passed the high-tech enterprise certification.
Toho Biotech (300239.SZ): Main products gelatin, collagen, capsules and terminal series products, etc.
Glonghui December 18丨Dongbao Biotech (300239.SZ) said on the investor interactive platform that the company's main products include gelatin, collagen, capsules and terminal products, etc., which are widely used in food, pharmaceuticals, health products, beauty and other fields. The company's collagen series products are basic nutrition and health products, mainly targeting middle-aged and elderly markets, women's markets, bone health markets, and sub-health markets.
No Data